What is Ikonisys?
Ikonisys SA, headquartered across Paris, New Haven, and Milan, is dedicated to the development, production, and marketing of the Ikoniscope20® platform. This fully-automated solution is engineered for the accurate and reliable detection and analysis of rare cells, a critical component in early cancer diagnosis. The company has achieved FDA clearance for several automated diagnostic applications, which are also available in Europe under CE certification. Ikonisys is actively expanding its offerings, with a focus on developing new tests, including those for liquid biopsies utilizing Circulating Tumor Cells (CTC). The company's enterprise-level funding indicates a mature stage of development and a focus on scaling its innovative technology.
How much funding has Ikonisys raised?
Ikonisys has raised a total of $56.4M across 10 funding rounds:
Unspecified
$3.8M
Unspecified
$1.4M
Debt
$117K
Debt
$6.3M
Share Placement
$535K
Share Placement
$208K
Other Financing Round
$541K
Unspecified (2010): $3.8M featuring Goldman Sachs and Trevi Health Ventures
Unspecified (2012): $1.4M backed by Trevi Health Ventures and Syneresis s.r.l.
Debt (2021): $117K with participation from PPP
Debt (2022): $6.3M led by Negma Group
Share Placement (2023): $535K supported by The Cambria Group
Share Placement (2024): $208K, investors not publicly disclosed
Other Financing Round (2025): $541K, investors not publicly disclosed
Key Investors in Ikonisys
New Science Ventures
New Science Ventures is a venture capital firm that invests in early and late-stage companies utilizing novel scientific approaches in the life sciences and information technology sectors, focusing on addressing significant unmet needs.
Trevi Health Ventures
Trevi Health Ventures is a specialist investment firm providing healthcare-focused alternative asset management, with an emphasis on medical devices, biopharmaceuticals, and healthcare services.
Lakeview Capital Management
Lakeview Capital Partners is an independent investment advisory firm providing investment management and wealth advisory services to high-net-worth individuals and families, endowments, and foundations.
What's next for Ikonisys?
With a history of substantial capital infusions, Ikonisys is poised for significant growth and market expansion. The recent strategic investment suggests a validation of its technological advancements and market strategy. Future endeavors will likely focus on broadening the application of its Ikoniscope20® platform, further developing its liquid biopsy tests, and potentially pursuing strategic partnerships to accelerate commercialization and global reach. The company's trajectory points towards solidifying its position as a leader in advanced cancer diagnostics.
See full Ikonisys company page
